Prognostic Value of PD-L1 expression in Patients with Anal Cancer: a Meta-analysis

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2024 May 3

PMID 38700275

Authors

Siqi Gong

Jiafeng Song

Affiliations

Soon will be listed here.

Abstract

The present meta-analysis was performed to evaluate the prognostic and clinicopathological significance of PD-L1 in anal cancer (AC). Hazard ratios (HRs) and 95% CIs regarding overall survival (OS) and progression-free survival (PFS) were calculated based on PD-L1 levels. According to the combined data, PD-L1 showed no significant relationship with OS (HR = 0.76; 95% CI = 0.35-1.67; p = 0.502) or PFS (HR = 0.88; 95% CI = 0.35-2.33; p = 0.789) in patients with AC. Based on subgroup analysis, PD-L1 overexpression significantly predicted prolonged OS (HR = 0.38; 95% CI = 0.17-0.84; p = 0.017) in tumor node metastasis stages I-III and inferior PFS (HR = 2.73; 95% CI = 1.32-5.65; p = 0.007) in patients with stage I-IV AC. PD-L1 level assessed by immunohistochemistry did not significantly predict survival outcomes in AC cases.

References

Gondal T, Chaudhary N, Bajwa H, Rauf A, Le D, Ahmed S . Anal Cancer: The Past, Present and Future. Curr Oncol. 2023; 30(3):3232-3250. PMC: 10047250. DOI: 10.3390/curroncol30030246. View

Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C . Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016; 7(22):32318-28. PMC: 5078015. DOI: 10.18632/oncotarget.8698. View

Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K . Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(6):653-677. DOI: 10.6004/jnccn.2023.0030. View

Liu X, Shan C, Song Y, Du J . Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Front Oncol. 2019; 9:1111. PMC: 6823255. DOI: 10.3389/fonc.2019.01111. View

Govindarajan R, Gujja S, Siegel E, Batra A, Saeed A, Lai K . Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. Am J Clin Oncol. 2016; 41(7):638-642. DOI: 10.1097/COC.0000000000000343. View

Hu Z, Lu L, Fei Z, Lv D . Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis. Transl Cancer Res. 2022; 9(9):5508-5516. PMC: 8798485. DOI: 10.21037/tcr-20-1512a. View

Troiano G, Caponio V, Zhurakivska K, Arena C, Pannone G, Mascitti M . High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. Cell Prolif. 2018; 52(2):e12537. PMC: 6495964. DOI: 10.1111/cpr.12537. View

Knudsen A, Rudkjobing S, Sorensen M, Dahlrot R, Kristensen B . Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas. J Neuropathol Exp Neurol. 2021; 80(6):541-551. DOI: 10.1093/jnen/nlab041. View

Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X . From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Front Immunol. 2022; 13:920021. PMC: 9382880. DOI: 10.3389/fimmu.2022.920021. View

10.

Chan A, Urgoiti G, Jiang W, Lee S, Kornaga E, Mathen P . The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy. Front Oncol. 2022; 12:1000263. PMC: 9585228. DOI: 10.3389/fonc.2022.1000263. View

11.

Hu Y, Chen W, Yan Z, Ma J, Zhu F, Huo J . Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019; 98(3):e14006. PMC: 6370132. DOI: 10.1097/MD.0000000000014006. View

12.

Shen H, Liu J, Sun G, Yan L, Li Q, Wang Z . The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Aging (Albany NY). 2020; 13(2):2279-2293. PMC: 7880326. DOI: 10.18632/aging.202248. View

13.

Martin D, Balermpas P, Gollrad J, Weiss C, Valentini C, Stuschke M . RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol. 2020; 23:43-49. PMC: 7218223. DOI: 10.1016/j.ctro.2020.04.010. View

14.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

15.

Daling J, Madeleine M, Johnson L, Schwartz S, Shera K, Wurscher M . Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004; 101(2):270-80. DOI: 10.1002/cncr.20365. View

16.

Moniz C, Riechelmann R, Oliveira S, Bariani G, Rivelli T, Ortega C . A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. J Cancer. 2021; 12(23):7018-7025. PMC: 8558650. DOI: 10.7150/jca.57678. View

17.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

18.

Xiao W, Yuan Y, Wang S, Liao Z, Cai P, Chen B . Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis. Front Immunol. 2022; 12:798451. PMC: 8794813. DOI: 10.3389/fimmu.2021.798451. View

19.

Monsrud A, Avadhani V, Mosunjac M, Flowers L, Krishnamurti U . Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. Arch Pathol Lab Med. 2021; 146(9):1094-1101. DOI: 10.5858/arpa.2021-0169-OA. View

20.

Tian L, Ma J, Ma L, Zheng B, Liu L, Song D . PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J Surg Oncol. 2020; 18(1):303. PMC: 7686719. DOI: 10.1186/s12957-020-02082-5. View